1.
Int J Antimicrob Agents
; 57(3): 106293, 2021 Mar.
Article
in English
| MEDLINE | ID: covidwho-1099125
Subject(s)
COVID-19 Drug Treatment , Chloroquine/analogs & derivatives , Chloroquine/adverse effects , Chloroquine/pharmacokinetics , Long QT Syndrome/chemically induced , Aged , Chloroquine/blood , Chloroquine/therapeutic use , Electrocardiography , Female , Humans , Male , Middle Aged , SARS-CoV-2/drug effects
2.
Ned Tijdschr Geneeskd
; 164, 2020.
Article
in Dutch
| PubMed | ID: covidwho-979350
ABSTRACT
Much has changed in the medical treatment of COVID-19 after the first patient with an infection with SARS-CoV-2 in the Netherlands was diagnosed in February 2020. On the basis of limited data, at first only off-label use of (hydroxy)chloroquine seemed to be a treatment option. However, now based on the findings of several randomized studies, other medicines have been included in the Dutch guidelines about the treatment of COVID-19. In this article, we will briefly discuss the current state of affairs with regard to the drugs (hydroxy) chloroquine, remdesivir and corticosteroids. Again, it appears that only well-executed randomized clinical trials can determine the status of various supposedly effective drugs.
3.
Nederlands Tijdschrift voor Geneeskunde
; 164(24), 2020.
Article
in Dutch
| Scopus | ID: covidwho-832648